Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL16295994 | 0.94 | CTSD (0.32) | CTSD | |
| SCHEMBL2230540 | 0.75 | CTSD (0.43) | CTSD | |
| Hydrochloric Acid SCHEMBL9079390 | 0.71 | CTSD (0.32) | CTSD | |
| Hydrochloric Acid SCHEMBL708751 | 0.71 | CTSD (0.37) | CTSD | |
| SCHEMBL27712901 | 0.69 | CTSD (0.35) | CTSD | |
| SCHEMBL2509325 | 0.69 | CTSD (0.35) | CTSD | |
| SCHEMBL28961651 | 0.67 | CTSD (0.38) | CTSD | |
| Hydrochloric Acid SCHEMBL9247457 | 0.67 | CTSD (0.33) | CTSD | |
| Hydrochloric Acid SCHEMBL22660514 | 0.67 | CTSD (0.33) | CTSD | |
| Hydrochloric Acid SCHEMBL1539601 | 0.67 | CTSD (0.33) | CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081278-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2017-03-23 | — | — | US | disclosed |
| US-9540318-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160304478-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-9428452-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| US-20150361039-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9150508-B2 | Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20150080369-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| EP-2841416-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2015-03-04 | — | — | EP | disclosed |
| US-20140243362-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| EP-2760443-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR | Glaxo Group Limited (GB) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013160418-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013045431-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| US-6303805-B1 | COMPLEX FOR OLEFIN OR STYRENE POLYMERIZATION PREPARED BY REACTING TRANSITION METAL COMPLEX AND COMPOUND HAVING AT LEAST TWO FUNCTIONAL GROUPS, HAVING STRUCTURE IN WHICH ANCILLARY LIGANDS OF COMPLEX ARE BRIDGED WITH SAID FUNCTIONAL GROUP | SAMSUNG GENERAL CHEMICAL CO., LTD. (KR) | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080369-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | CTSD 4091/4885 |
| US-20170081278-A1 | Novel compounds | RORC, RORB, RORA | CTSD 4091/4885 |
| US-20150361039-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | RORA, RORC, RORB | CTSD 4134/4885 |
| US-20140243362-A1 | SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR | RORA, RORB, RORC | CTSD 4288/4885 |
| US-20160304478-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | CTSD 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.